Federal preemption fails in award against Wyeth products

Share this article:
Federal preemption arguments failed in October to prevent a Nevada jury from awarding three women $134.5 million in their suit against Wyeth over its hormone replacement products Premarin and Prempro that they alleged caused their breast cancer. Later, the presiding judge slashed $100 million from the award as improperly punitive and ordered the jury to reconsider it.

The award was seen as daunting for Wyeth as it defends more than 5,000 similar lawsuits across the country. A penalty phase of the trial continues, which could lead to more monetary damages.
Preemption arguments were first raised in Wyeth's 2004 answer to the plaintiffs' complaint. The company said plaintiffs' claims that its products were unsafe are barred by the doctrine of preemption and the Supremacy Clause of the Constitution.

“Any claim for injunctive relief is preempted or barred by federal law because such a claim would impede, frustrate and burden the effectiveness of federal law regulating the field of prescription drugs; require Wyeth to meet conflicting obligations under federal and state law; and constitute an invalid burden on interstate commerce…,” it said.

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"